Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab
- PMID: 17639745
- DOI: 10.1097/SMJ.0b013e318048589e
Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab
Abstract
Background: The aims of this study are to define the length of the respiratory syncytial virus (RSV) season throughout Florida and evaluate the American Academy of Pediatrics (AAP) guidelines on the administration of palivizumab in light of the Florida data.
Methods: We retrospectively analyzed four seasons of monthly RSV surveillance data housed on the Florida Department of Health website for regional trends in RSV outbreaks.
Results: RSV circulated year round in Florida, with December being the peak month for RSV activity statewide. Regional virology data showed consistent patterns throughout the observation period, and all regions experienced widespread RSV activity for at least seven months of the year. The southeast region experienced the longest RSV seasons (10-12 mo), with year round outbreaks observed during 2000 to 2001 and 2001 to 2002.
Conclusions: Local RSV surveillance provides meaningful data to guide decisions on the administration of palivizumab. Reliance on current AAP guidelines for RSV prophylaxis would result in under-protection of at-risk children in all regions within the state of Florida.
Comment in
-
Respiratory syncytial virus: different criteria for palivizumab use in different areas?South Med J. 2007 Jul;100(7):661-2. doi: 10.1097/SMJ.0b013e318070ca99. South Med J. 2007. PMID: 17639741 No abstract available.
-
Response to respiratory synctial virus.South Med J. 2008 Feb;101(2):212-3; author reply 213-4. doi: 10.1097/SMJ.0b013e3181611d5f. South Med J. 2008. PMID: 18364631 No abstract available.
Similar articles
-
Correlation between respiratory syncytial virus (RSV) test data and hospitalization of children for RSV lower respiratory tract illness in Florida.Pediatr Infect Dis J. 2008 Jun;27(6):512-8. doi: 10.1097/INF.0b013e318168daf1. Pediatr Infect Dis J. 2008. PMID: 18449062
-
Use of respiratory syncytial virus surveillance data to optimize the timing of immunoprophylaxis.Pediatrics. 2010 Jul;126(1):e116-23. doi: 10.1542/peds.2009-3221. Epub 2010 Jun 14. Pediatrics. 2010. PMID: 20547651
-
Respiratory syncytial virus: different criteria for palivizumab use in different areas?South Med J. 2007 Jul;100(7):661-2. doi: 10.1097/SMJ.0b013e318070ca99. South Med J. 2007. PMID: 17639741 No abstract available.
-
Palivizumab for respiratory syncytial virus prophylaxis.J Pediatr Health Care. 1999 Jul-Aug;13(4):191-5; quiz 196-7. doi: 10.1016/S0891-5245(99)90039-1. J Pediatr Health Care. 1999. PMID: 10690084 Review.
-
A review of palivizumab and emerging therapies for respiratory syncytial virus.Expert Opin Biol Ther. 2011 Nov;11(11):1455-67. doi: 10.1517/14712598.2011.608062. Epub 2011 Aug 11. Expert Opin Biol Ther. 2011. PMID: 21831008 Review.
Cited by
-
Respiratory syncytial virus seasonality and its implications on prevention strategies.Hum Vaccin Immunother. 2018 Jan 2;14(1):234-244. doi: 10.1080/21645515.2017.1403707. Epub 2017 Dec 15. Hum Vaccin Immunother. 2018. PMID: 29194014 Free PMC article. Review.
-
Epidemiology of respiratory syncytial virus in various regions within North Carolina during multiple seasons.N C Med J. 2008 Nov-Dec;69(6):447-52. N C Med J. 2008. PMID: 19256181 Free PMC article.
-
Understanding the local-level variations in seasonality of human respiratory syncytial virus infection: a systematic analysis.BMC Med. 2025 Jan 29;23(1):55. doi: 10.1186/s12916-025-03888-4. BMC Med. 2025. PMID: 39881360 Free PMC article.
-
Global Seasonal Activities of Respiratory Syncytial Virus Before the Coronavirus Disease 2019 Pandemic: A Systematic Review.Open Forum Infect Dis. 2024 Apr 25;11(5):ofae238. doi: 10.1093/ofid/ofae238. eCollection 2024 May. Open Forum Infect Dis. 2024. PMID: 38770210 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous